EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis

Mary Jo Lechowicz, Christy Smith, Robert Ristuccia, Karen Dwyer

International Journal of Hematology · 2024

DOI: 10.1007/s12185-024-03753-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Hematology, 2024. Verfasst von Mary Jo Lechowicz und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Winship Cancer Institute, Emory University, Atlanta, GA, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Transplantation, Homologous. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kyowa Kirin Pharmaceutical Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important therapy for patients with T-cell lymphomas, including cutaneous T-cell lymphoma (CTCL), adult T-cell lymphoma (ATL), and peripheral T-cell lymphoma (PTCL). Mogamulizumab is an anti-CCR4 antibody that has been associated with an increased risk of transplant-related complications in retrospective analyses of ATL, particularly when administered within 50 days before transplantation. This post hoc analysis of 3 clinical trials examined safety and outcome data for 32 patients with CTCL ( n = 23), ATL ( n = 7), or PTCL ( n = 2) who underwent allo-HSCT after mogamulizumab treatment. Overall, 22 patients (69%) were known to have graft-versus-host disease (GVHD), 8 patients (25%) did not report GVHD, and 2 patients (6%) had unknown GVHD status. Fourteen patients with known GVHD underwent transplantation between 50 and 365 days after their last dose of mogamulizumab, while 2 underwent transplantation within 50 days after treatment. Based on this limited evidence, GVHD was not associated with the time interval from last mogamulizumab dose to transplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedHematopoietic Stem Cell TransplantationGraft vs Host DiseaseTransplantation, HomologousHumansRetrospective StudiesMiddle AgedMaleFemaleAdultAgedLymphoma, T-CellTreatment Outcome

Stichwörter der Autor:innen

LymphomaMogamulizumabT cellTransplant

Substanzen

mogamulizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • The Winship Cancer Institute, Emory University, Atlanta, GA, USA.
  • Medical Affairs Oncology, Kyowa Kirin, Inc, Princeton, NJ, USA.
  • Medical Affairs Oncology, Kyowa Kirin, Inc, Princeton, NJ, USA. robert.ristuccia.bt@kyowakirin.com.
  • Medical Sciences, Kyowa Kirin, Inc, Princeton, NJ, USA.

Förderung

  • Kyowa Kirin Pharmaceutical Development

Zitieren

APA

Lechowicz, M. J., Smith, C., Ristuccia, R., & Dwyer, K. (2024). Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03753-9

Vancouver

Lechowicz MJ, Smith C, Ristuccia R, Dwyer K. Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis. International Journal of Hematology. 2024. doi:10.1007/s12185-024-03753-9

BibTeX
@article{Lechowicz2024,
  author = {Lechowicz, Mary Jo and Smith, Christy and Ristuccia, Robert and Dwyer, Karen},
  title = {Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis},
  journal = {International Journal of Hematology},
  year = {2024},
  doi = {10.1007/s12185-024-03753-9}
}
Kostenlos starten →